| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/978-3-319-13150-4_5 |
| P698 | PubMed publication ID | 25655608 |
| P50 | author | Tarec Christoffer El-Galaly | Q41600193 |
| Martin Hutchings | Q57612784 | ||
| P2093 | author name string | Tarec Christoffer El-Galaly | |
| P2860 | cites work | A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project | Q28251216 |
| A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma | Q28254924 | ||
| The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP | Q28274089 | ||
| 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation | Q33606294 | ||
| Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group | Q33773306 | ||
| Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas | Q33781006 | ||
| Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas | Q74774489 | ||
| Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET | Q80206194 | ||
| Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT | Q80413759 | ||
| FDG-PET in T-cell and NK-cell neoplasms | Q80837973 | ||
| Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center | Q83397934 | ||
| Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy | Q87402740 | ||
| Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study | Q33913959 | ||
| Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia | Q34009015 | ||
| The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma | Q34190099 | ||
| Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas | Q34283822 | ||
| Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis | Q34355722 | ||
| Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification | Q34663865 | ||
| Assessment of response to therapy using conventional imaging | Q35094205 | ||
| Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement | Q35871945 | ||
| Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma | Q36715057 | ||
| Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma | Q36836092 | ||
| Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma | Q36911505 | ||
| Imaging in staging of malignant lymphoma: a systematic review | Q36960797 | ||
| Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. | Q37040596 | ||
| Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. | Q37216194 | ||
| Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. | Q37240835 | ||
| High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens | Q37321768 | ||
| Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma | Q37326204 | ||
| 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma. | Q37561054 | ||
| A decade of progress in lymphoma: advances and continuing challenges | Q37820762 | ||
| PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study | Q38179303 | ||
| Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. | Q38184954 | ||
| Advanced-stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission--a randomized trial of routine surveillance imaging procedures. | Q38202697 | ||
| [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. | Q38209637 | ||
| The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma: a comparison with conventional staging methods | Q38450591 | ||
| Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants | Q39730021 | ||
| (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients | Q39919495 | ||
| Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment | Q39950405 | ||
| FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome | Q39957677 | ||
| Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). | Q40282196 | ||
| Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma | Q42934424 | ||
| Pitfalls in imaging Hodgkin's disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose | Q43658216 | ||
| Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation | Q43882760 | ||
| Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation | Q44016076 | ||
| Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma | Q44073105 | ||
| Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma | Q44114749 | ||
| Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma. | Q44207367 | ||
| Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation | Q44333094 | ||
| Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma | Q44391203 | ||
| 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation. | Q44438293 | ||
| Early therapy monitoring with FDG-PET in aggressive non-Hodgkin?s lymphoma and Hodgkin?s lymphoma | Q44629028 | ||
| Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission | Q45244780 | ||
| Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. | Q46052641 | ||
| Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. | Q46086916 | ||
| Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma | Q46094228 | ||
| Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate | Q46190179 | ||
| Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. | Q46309065 | ||
| Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma? | Q46317418 | ||
| [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. | Q46463095 | ||
| FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. | Q46568257 | ||
| The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. | Q46638000 | ||
| Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. | Q46642659 | ||
| Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? | Q46726584 | ||
| Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma | Q46736825 | ||
| Revised response criteria for malignant lymphoma | Q47582438 | ||
| F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma. | Q53083162 | ||
| PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. | Q53109949 | ||
| Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. | Q53120165 | ||
| SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. | Q53154628 | ||
| Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. | Q53155071 | ||
| A pilot study to evaluate 3'-deoxy-3'-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma. | Q53192631 | ||
| Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria. | Q53230865 | ||
| Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT. | Q53242737 | ||
| Comparison of 11C-methionine PET and 18F-FDG PET in patients with primary central nervous system lymphoma | Q53262992 | ||
| Follicular lymphoma international prognostic index. | Q53289840 | ||
| Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. | Q53470993 | ||
| Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. | Q53497464 | ||
| Molecular imaging of proliferation in malignant lymphoma. | Q53512276 | ||
| FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. | Q53515118 | ||
| Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. | Q53540097 | ||
| Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. | Q54117465 | ||
| Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q59273877 | ||
| Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study | Q61774252 | ||
| Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions | Q68952968 | ||
| On the problem of linear incorporation of amino acids into cell protein | Q70426771 | ||
| Altered methionine metabolism occurs in all members of a set of diverse human tumor cell lines | Q71300983 | ||
| 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT | Q73850063 | ||
| Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial | Q74082930 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 125-146 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Cancer Treatment and Research | Q15763626 |
| P1476 | title | Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies | |
| P478 | volume | 165 |
| Q89207688 | 18F-FDG PET/MRI in patients suffering from lymphoma: how much MRI information is really needed? |
| Q37428422 | A novel non-Hodgkin lymphoma murine model closer to the standard clinical scenario |
| Q53692405 | Inter-Observer Agreement of Whole-Body Computed Tomography in Staging and Response Assessment in Lymphoma: The Lugano Classification. |
| Q26765882 | Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring |
Search more.